[{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Announces Publication of Positive Efficacy Data With Sitoiganap in Patients With Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Partnering with Leading Academic Cooperative Groups to Study Amcenestrant in the Adjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Breast International Group"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"Dynacure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Flamingo Therapeutics"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"VLAIO","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics Receives \u20ac1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Flamingo Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The funding will advance Flamingo's RNA-targeting oncology portfolio, including translational research for its lead clinical program, AZD9150 (danvatirsen) in Phase II in head and neck squamous cell carcinoma, and preclinical work on its LncRNA program targeting MALAT-1.
The combined oncology company will advance Flamingo's lead programs, Danvatirsen (antisence oligonucleotide) in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting MALAT-1 in cancer.
Lead Product(s):
Antisence Oligonucleotide,Pembrolizumab
Gliovac (sitoiganap/ERC 1671) is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM,Such tumor tissue is then processed to obtain inactivated intact cells and disrupted lysed cells from different patients.
Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue standard therapy.
The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients who have exhausted all other treatment options.
The MAA contains observations suggesting safety and efficacy of SITOIGANAP demonstrated from the interim data of a randomized double-blind phase II trial.